利奥西呱治疗早期肺血管疾病:一项前瞻性、多中心、随机、双盲、安慰剂对照2a期试验的疗效与安全性
这项前瞻性、多中心、双盲2a期试验纳入35例早期肺血管疾病成人患者(平均肺动脉压≥25 mmHg且PVR≥2至<3 WU,或平均肺动脉压21至<25 mmHg且PVR≥2 WU),1:1随机接受利奥西呱或安慰剂治疗24周。仅观察到轻至中度不良事件,严重事件被认为与治疗无关。
要点
- 适用人群为早期肺血管疾病成人:平均肺动脉压≥25 mmHg且PVR≥2至<3 WU,或平均肺动脉压21至<25 mmHg且PVR≥2 WU。
- 心脏指数、总肺阻力、DLCO、6分钟步行距离、WHO功能分级及生活质量等次要终点均无显著差异。
- 仅观察到轻至中度不良事件,严重事件被认为与治疗无关。
适用人群与场景
- 成人早期肺血管疾病患者:平均肺动脉压≥25 mmHg且PVR≥2至<3 WU,或平均肺动脉压21至<25 mmHg且PVR≥2 WU。
- 随机化35例中97%为女性,平均年龄65.5±6.9岁,77.1%为结缔组织病相关肺动脉高压。
- 32例完成试验。
诊断标准与关键阈值
- 早期肺血管疾病定义:平均肺动脉压≥25 mmHg且PVR≥2至<3 WU,或平均肺动脉压21至<25 mmHg且PVR≥2 WU。
处置流程与药物剂量
- 利奥西呱或安慰剂1:1随机,治疗24周;具体剂量、给药途径及频次原文未提及。
- 主要终点为PVR从基线至第24周的变化。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:前瞻性、多中心、随机、双盲、安慰剂对照2a期试验;35例随机,32例完成。
- 次要终点(心脏指数、总肺阻力、DLCO、6分钟步行距离、WHO功能分级、生活质量)均无显著差异。
- 安全性:仅轻至中度不良事件,严重事件被认为与治疗无关。
证据类型、等级与局限
- 证据类型:随机双盲安慰剂对照2a期试验。
- 局限:样本量小(35例随机),原文承认参与者数量有限。
对床旁实践的改变
- 在早期肺血管疾病患者中,利奥西呱治疗24周可显著改善PVR,但次要终点(包括6分钟步行距离、WHO功能分级、生活质量)均无显著改善,不能据此推荐以症状或功能改善为目的的常规使用。
- 适用人群严格限定为原文定义的早期肺血管疾病(平均肺动脉压≥25 mmHg且PVR≥2至<3 WU,或平均肺动脉压21至<25 mmHg且PVR≥2 WU),不适用于其他肺动脉高压人群。
- 样本量小(35例),结果需进一步验证,不能作为常规治疗决策依据。
指南或共识出处
- 原文未提及指南或共识名称;试验注册号NCT05339087。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Pulmonary arterial hypertension therapies have not been systematically studied in early disease stages, despite potential benefit.
RESEARCH QUESTION: Is riociguat safe, well tolerated, and potentially effective in early pulmonary vascular disease?
STUDY DESIGN AND METHODS: This was a prospective, multicenter, double-blind phase 2a trial. Adults with early pulmonary vascular disease, defined as mean pulmonary arterial pressure ≥ 25 mm Hg with pulmonary vascular resistance (PVR) ≥ 2 to < 3 Wood units (WU), or mean pulmonary arterial pressure 21 to < 25 mm Hg with PVR ≥ 2 WU, were randomized to receive 1:1 riociguat or placebo for 24 weeks. The primary end point was change in PVR from baseline to week 24. Secondary end points, evaluated hierarchically, comprised changes in cardiac index, total pulmonary resistance, diffusing capacity of the lung for carbon monoxide, 6-minute walking distance, World Health Organization functional class, and quality of life. Complementary parameters were analyzed in an exploratory manner, and safety was monitored throughout.
RESULTS: Of 261 prescreened patients, 35 eligible patients were randomized to treatment (97% female; mean age, 65.5 ± 6.9 years; 77.1% connective tissue disease-associated pulmonary arterial hypertension); 32 completed the trial. Reasons for ineligibility were documented. Riociguat significantly improved the primary end point of change in PVR (riociguat -0.73 ± 0.67 WU vs placebo -0.02 ± 0.67 WU; P = .043; 27% placebo-adjusted reduction). No significant differences were observed in secondary end points. Of the exploratory end points, only cardiac output showed a trend toward improvement under riociguat (0.35 ± 0.86 L/min vs placebo -0.19 ± 0.75 L/min; P = .084). Only mild to moderate adverse events were observed, and serious events were not considered treatment related.
INTERPRETATION: Despite the limited number of participants, treatment with riociguat was safe and significantly improved the primary end point PVR over 24 weeks.
CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT05339087; URL: www.
CLINICALTRIALS: gov).
参考来源
- Xanthouli P, Benjamin N, Coghlan G, et al. Efficacy and Safety of Riociguat in Early Pulmonary Vascular Disease: A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2a Trial. Chest. 2026. PMID: 42457022. doi:10.1016/j.chest.2026.06.053
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。